Takeda Commits $100M for Chance to Bring Immunotherapy to Alzheimer’s Disease

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Takeda Pharmaceutical has secured an option on an Alzheimer’s disease immunotherapy from AC Immune that is on track to report its first Phase 2 data later this quarter. Exercising the option would make Takeda responsible for Phase 3 testing of the therapy, putting AC Immune in line for up to $2.1 billion in milestone payments.

The post Takeda Commits $100M for Chance to Bring Immunotherapy to Alzheimer’s Disease appeared first on MedCity News.

Leave a Replay

Sign up for our Newsletter

Contact Us